Skip to main content

Advertisement

SpringerLink
Log in

The role of prostate-specific antigen velocity in prostate cancer early detection

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Prostate-specific antigen velocity (PSAV) is the rate of change in prostate-specific antigen (PSA) values with repeated measurement over time. Accurate use of PSAV for prostate cancer early detection requires the use of two or more PSA levels collected over approximately 1.5 to 2 years. When these specimen collection criteria are met, more than 95% of men without prostate cancer will have a PSAV less than 0.75 ng/mL/y, whereas approximately 70% of men with prostate cancer will have a PSAV above this threshold. PSAV is thus more specific than routine PSA testing for the presence of prostate cancer, because few men (< 5%) without prostate cancer have a PSAV sufficient to trigger prostate biopsy. The use of PSAV in the increasing number of men with lengthy PSA histories obtained in systematic efforts at prostate cancer early detection may aid in diagnosing prostate cancer and spare some men unnecessary prostate biopsy. This review briefly summarizes the theoretic basis and clinical utility of PSAV in prostate cancer early detection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990, 194:755–763.

    Article  PubMed  CAS  Google Scholar 

  2. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK: Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974–1994. J Urol 1997, 158:1427–1430.

    Article  PubMed  CAS  Google Scholar 

  3. Gann PH: Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 1997, 8:117–120.

    PubMed  CAS  Google Scholar 

  4. Catalona WJ, Richie JP, Ahmann FR, et al.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994, 151:1283–1290.

    PubMed  CAS  Google Scholar 

  5. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995, 273:289–294.

    Article  PubMed  CAS  Google Scholar 

  6. Eyre HJ, Feldman GE: Status report on prostate cancer in African-Americans: a national blueprint for action. CA Cancer J Clin 1998, 48:315–319.

    PubMed  CAS  Google Scholar 

  7. Farkas A, Schneider D, Perrotti M, et al.: National trends in epidemiology of prostate cancer, 1973–1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998, 52:444–448. The authors compile epidemiologic data detailing the effects of PSA-based screening programs on prostate cancer incidence and stage migration.

    Article  PubMed  CAS  Google Scholar 

  8. Mettlin C, Jones G, Averett H et al.: Defining and updating the American Cancer Society guidelines for the cancer-related checkup. Prostate and endometrial cancers. CA Cancer J Clin 1993, 43:42–46.

    PubMed  CAS  Google Scholar 

  9. American Urological Association Policy Statement. Early Detection of Prostate Cancer and Use of Transrectal Ultrasound. Policy Statement Book. Baltimore:American Urological Association; 1992:4–20.

    Google Scholar 

  10. Potter SR, Partin AW: National Comprehensive Cancer Network Practice guidelines for early detection of prostate cancer. Oncology 1999, 13:99–115. The authors provide a cogent review of issues surrounding efforts at prostate cancer early detection in reporting the guidelines of the National Comprehensive Cancer Network.

    Google Scholar 

  11. Carter HB, Partin AW: Diagnosis and staging of prostate cancer. In Campbell’s Urology, vol 3, edn 7. Edited by Walsh PC, Retik AB, Vaughan ED, Wein AJ. Philadelphia:WB Saunders; 1998:2519–2537.

    Google Scholar 

  12. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270:948–954.

    Article  PubMed  CAS  Google Scholar 

  13. Littrup PJ, Kane RA, Mettlin CJ, et al.: Cost-effective prostate cancer detection. Reduction if low-yield biopsies. Investigators of the American Cancer Society National Prostate Detection Project. Cancer 1994, 74:3146–3158.

    Article  PubMed  CAS  Google Scholar 

  14. Ercole CJ, Lange PH, Mathiesen M, et al.: Prostate-specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987, 138:1181–1184.

    PubMed  CAS  Google Scholar 

  15. Nadler RB, Humphrey PA, Smith DS, et al.: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1993, 154:407–413.

    Article  Google Scholar 

  16. Nixon RG, Brawer MK: Enhancing the specificity of prostatespecific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br J Urol 1997, 79(suppl 1):61–67.

    PubMed  Google Scholar 

  17. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 143:1146–1154.

    Google Scholar 

  18. Partin AW, Carter HB, Chan DW, et al.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990, 143:747–752.

    PubMed  CAS  Google Scholar 

  19. Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989, 141:1076–1083.

    PubMed  CAS  Google Scholar 

  20. Meyer JS, Sufrin G, Martin SA: Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J Urol 1982, 128:1353–1356.

    PubMed  CAS  Google Scholar 

  21. Carter HB, Pearson JD: Evaluation of changes in PSA in the management of men with prostate cancer. Semin Oncol 1994, 21:554–559.

    PubMed  CAS  Google Scholar 

  22. Schock NW, Greulich RC, Andres R, et al.: Normal Human Aging: the Baltimore Longitudinal Study of Aging. Washington, DC: National Institutes of Health, publication no. 84-2450. United States Government Printing Office; 1984.

    Google Scholar 

  23. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of Finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  24. Carter HB, Pearson JD, Metter EJ, et al.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JaMA 1992, 267:2215–2220.

    Article  PubMed  CAS  Google Scholar 

  25. Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994, 152:1743–1758.

    PubMed  CAS  Google Scholar 

  26. Carter HB, Pearson JD, Waclawiw Z, et al.: Prostate-specific antigen variability in men without prostate cancer: the effect of sampling interval and number of repeat measurements on prostate-specific antigen velocity. Urology 1995, 45:591–595.

    Article  PubMed  CAS  Google Scholar 

  27. Carter HB, Pearson JD: Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 1997, 24:333–338.

    Article  PubMed  CAS  Google Scholar 

  28. Kadmon D, Weinberg AD, Williams RH, et al.: Pitfalls in interpreting prostate specific antigen velocity. J Urol 1996, 155:1655–1657.

    Article  PubMed  CAS  Google Scholar 

  29. Komatsu K, Wehner N, Prestigiacomo AF, et al.: Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996, 47:343–346.

    Article  PubMed  CAS  Google Scholar 

  30. Riehmann M, Rhodes PR, Cook TD, et al.: Analysis of variation in prostate-specific antigen values. Urology 1993, 42:390–397.

    Article  PubMed  CAS  Google Scholar 

  31. Roehrborn CG, Pickens GJ, Carmody T: Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 1996, 47:59–66.

    Article  PubMed  CAS  Google Scholar 

  32. Mettlin C, Littrup PJ, Kane RA, et al., for the Investigators of the American Cancer Society National Prostate Cancer Detection Project: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994, 74:1615–1620.

    Article  PubMed  CAS  Google Scholar 

  33. Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994, 152:1163–1167.

    PubMed  CAS  Google Scholar 

  34. Lujan M, Paez A, Sanchez E, et al.: Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol 1999, 162:1311–1313.

    Article  PubMed  CAS  Google Scholar 

  35. Harris CH, Dalkin BL, Martin E, et al.: Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/mL or less. J Urol 1997, 157:1740–1743.

    Article  PubMed  CAS  Google Scholar 

  36. Yuan JJ, Coplen DE, Petros JA, et al.: Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels. J Urol 1992, 147:810–814.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Urology, Marburg 205A, The Johns Hopkins Hospital, 600 North Wolfe Street, 21287-2101, Baltimore, MD, USA

    Steven R. Potter MD & H. Ballentine Carter MD

Authors
  1. Steven R. Potter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Ballentine Carter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Potter, S.R., Carter, H.B. The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep 1, 15–19 (2000). https://doi.org/10.1007/s11934-000-0030-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-000-0030-4

Keywords

Search

Navigation